Explore the latest advancements in HIV therapy and how enhanced immune cells can improve treatment outcomes for patients.
News Medical on MSN
11th Innate Killer Summit returns to San Diego, showcasing clinical data that signals renewed momentum in NK cell therapy
March 23-25, 2026 | San Diego, CA The 11th Innate Killer Summit returns, bringing together global leaders advancing natural killer (NK) cell–based immunotherapies. The meeting continues as the longest ...
More than 30 million people with HIV must take antiretroviral therapy (ART) medications daily to keep the virus under control, according to the Joint United Nations Programme on HIV/AIDS (UNAIDS). The ...
First Phase 2 chemotherapy-free, lymphodepletion-free, off-the-shelf CAR-NK cell therapy plus ANKTIVA® and rituximab regimen ...
CD19 CAR NK cell therapy, alone or with rituximab, shows promise in relapsed/refractory B-cell NHL, including Waldenström macroglobulinemia. Two heavily pretreated WM patients achieved complete ...
A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a CD30/CD16A bispecific antibody, was safe and generated strong response rates ...
Durable complete responses with CAR-NK + Rituximab in patients who failed current standards of care in Waldenstrom’s Non-Hodgkins lymphoma (NHL). Long-term evaluable patients demonstrate ongoing ...
Phase 1/2 clinical study of NY-ESO-1 TCR/IL-15 NK for relapsed or refractory multiple myeloma commences on track NY-ESO-1 TCR/IL-15 NK is the lead clinical program of Syena, a Replay and MD Anderson ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results